Pharmacokinetics of Deramciclane, a Novel Anxiolytic Agent, after Intravenous and Oral Administration

@article{Huupponen2003PharmacokineticsOD,
  title={Pharmacokinetics of Deramciclane, a Novel Anxiolytic Agent, after Intravenous and Oral Administration},
  author={R. Huupponen and O. Paija and M. Salonen and Harry Bj{\"o}rklund and J. Rouru and M. Anttila},
  journal={Drugs in R \& D},
  year={2003},
  volume={4},
  pages={339-345}
}
AbstractBackground and objective: Deramciclane is a new compound that has shown anxiolytic effects in animal experiments and in human studies. The aim of this study was to determine the pharmacokinetic parameters of deramciclane after intravenous and oral administration, and its oral bioavailability. Methods: Deramciclane 30mg was given intravenously and orally as a tablet and as solution in an open, randomised, crossover three-period trial to 12 healthy male volunteers. Oral bioavailability… Expand
1 Citations
Synthesis of deramciclane* labeled with tritium in various positions
[(1R)-endo]-(+)-3-bromocamphor was dehalogenated with tritium gas to [3-3H]camphor and via [3-3H]phenylborneol converted to [3-3H]deramciclane isolated as the fumarate salt (specific activity 51.8Expand

References

SHOWING 1-8 OF 8 REFERENCES
Pharmacokinetics of deramciclane in dogs after single oral and intravenous dosing and multiple oral dosing
TLDR
It is suggested that the metabolic capacity was not sufficient to eliminate deramciclane in a linear manner with increasing dose as the AUC0–∞ increased disproportionally to the dose after both intravenous and oral dosing. Expand
Pharmacokinetics and safety of deramciclane during multiple oral dosing.
TLDR
The pharmacokinetics of deramciclane is linear over the dose range of 10 - 60 mg at steady-state and the slight non-linearity within the dose levels during repeated administration of seven days was regarded as clinically irrelevant. Expand
The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers
TLDR
The pharmacokinetics and tolerability of a new putative non‐benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies and was safe, and was well tolerated at each dose level. Expand
Pharmacokinetics of Deramciclane in Dogs
The pharmacokinetic properties of deramciclane fumarate (EGIS-3886; (1R,2S,4R)-(–)-N,N-dimethyl-2-[(1,7,7-trimethyl-2-phenylbicyclo-[2,2,1]-hept-2-yl)oxy]ethanamine-2-(E)-butendioate (1 : 1)), a newExpand
Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation
TLDR
Data indicate that deramciclane is a 5- HT2C receptor inverse agonist and occupies 5-HT2C receptors during treatment, and that chronic treatment with deramCiclane does not lead to5-HT 2C receptor down-regulation. Expand
Receptor binding profile and anxiolytic‐type activity of deramciclane (EGIS‐3886) in animal models
The present series of experiments was done to characterize the properties of deramciclane, a new antiserotonergic drug, in both receptor binding studies in vitro and in a number of anxiolytic,Expand
Goodman & Gilman's The Pharmacological Basis of Therapeutics
TLDR
Goodman and Gilman's the pharmacological basis of therapeutics , Goodman and Gilmann's the pharmaceutica basis for drug discovery, and more. Expand